Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Exscientia Ltd.

www.exscientia.co.uk

Latest From Exscientia Ltd.

Sanofi/Google Alliance To Apply Big Data To R&D, Commercial And Marketing Operations

Sanofi says the virtual innovation lab it will create with Google will enable precision health care and optimize R&D and commercial operations. Incoming CEO Hudson has been tasked with improving the pharma’s R&D and digital capabilities.

Deals Digital Health

Finance Watch: Tetraphase Reorganization Follows Troubled Antibiotic Commercialization Path

Tetraphase's plan to downsize may put the company on the same path as now-bankrupt Achaogen. Also, Bain raises $900m for its second life science fund, Provention calls off post-ADA offering and Oncologie raises $80m series B.

Financing Business Strategies

Asia Deal Watch: Everest Licenses Asia Rights To Calliditas’ IgA Nephropathy Candidate

While an orphan indication in the US and EU, IgAN accounts for 40% of glomerular disease in China; deal also confers rights in Hong Kong, Macau, Taiwan, Singapore. Also, Y-Biologics teams with Dualogics on bispecific antibodies for cancer.

Business Strategies Deals

How Can Korea Grab Window Of Opportunity In AI Drug Development?

Participants at a recent policy forum in Seoul stressed the need to secure appropriate technology and expertise, unify government support and draw up a joint cooperation plan between industry and government as key factors in advancing AI-guided new drug development in South Korea.

South Korea Artificial Intelligence
See All

Company Information

  • Industry
  • Biotechnology
    • Drug Discovery Tools
  • Digital Health
  • Pharmaceuticals
  • Services
  • Therapeutic Areas
  • Cancer
  • Metabolic Disorders
  • Neurology, Nervous System
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • UK
  • Parent & Subsidiaries
  • Exscientia Ltd.
  • Senior Management
  • Andrew Hopkins, CEO
    Georgy Egorov, CFO
    Mark Swindells, PhD, COO
    Jeremy Besnard, PhD, Chief Designer
    Richard Bickerton, PhD, CIO
    Andy Bell, PhD, Chief Research officer
    Richard Cox, MSc, Dir, Engineering
    Adrian Schreyer, PhD, CTO
    Heather Togwell, Ops Manager
  • Contact Info
  • Exscientia Ltd.
    Dundee Incubator, James Lindsay Place
    Lab 12
    Dundee, DD1 5JJ
    UK
Advertisement
Advertisement
UsernamePublicRestriction

Register